Breast Cancer
Opinion
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...
From the Journals
Trastuzumab benefit lasts long-term in HER2+ breast cancer
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR...
Conference Coverage
Adding veliparib to chemotherapy improves PFS in BRCA-mutated breast cancer
BARCELONA – Adding veliparib to chemotherapy improved PFS and provided more durable benefit than did chemotherapy...
From the Journals
Risk of contralateral breast cancer highest for women under 40
Investigators predict 28% of the increased risk of contralateral breast cancer was attributable to stray radiation exposure.
From the Journals
Multigene testing for all patients with breast cancer may be cost-effective, life-saving
Modeling suggests high-risk multigene testing for all breast cancer patients might be cost-effective, but critics suggest “true costs are hidden...
Conference Coverage
Ribociclib/fulvestrant boosts survival in advanced breast cancer
BARCELONA – The median overall survival for patients who received the CDK4/6 inhibitor plus fulvestrant has not been reached in the MONALEESA-3...
From the Journals
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
Conference Coverage
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
BARCELONA – MONARCH 2 trial data show that adding the CDK4/6 inhibitor abemaciclib to fulvestrant significantly improves overall survival in HR+,...
Latest News
Gene recurrence score helps predict successful combination therapy for early breast cancer
Women with a high recurrence score on a 21-gene breast cancer assay fared better with chemoendocrine therapy than expected with endocrine therapy...
From the Journals
Physicians not yet comfortable with using social media to recruit for trials
In interviews, many physicians expressed interest but would like to have institutional support, guidelines, and training.
From the Journals
AF risk is elevated after early-stage breast cancer diagnosis
The rate of AF was elevated in the first year post diagnosis and after 5 years post diagnosis, with greater elevation for women who received...